Week of October 18th 2021 | Vol. 10, Issue 42
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Repairing neurological damage caused by stroke, Parkinson’s disease and other brain conditions isn’t all fun and games, but digital therapeutics developers like MindMaze are aiming to bring a bit of levity to what can otherwise be a difficult and stressful process. MindMaze’s platform comprises a series of video games that, when combined with a motion-tracking camera and customized to a patient’s individual condition and needs, can support both rehabilitation and restoration of brain function.

Several of the programs have already been cleared for use in the U.S. and Europe, and a new line of funding will now help make them even more widely available. The financing came courtesy of London-based AlbaCore Capital Group and totaled $125 million. That builds on MindMaze’s previous megaround, which raked in $100 million in early 2016 and was led by the U.K.’s Hinduja Group. With the addition of the new funding, MindMaze has now achieved the elusive unicorn status, with an estimated valuation of $1.5 billion, per Bloomberg.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
12 transactions totaling $1,636 million
Supplies, Equipment & Services
18 transactions totaling $248 million
Healthcare IT & Managed Care
3 transactions totaling $17 million
Healthcare Facilities & Distributors
5 transactions totaling $71 million
Pharma & Biotech
19 transactions totaling $350 million
Supplies, Equipment & Services
24 transactions totaling $403 million
Healthcare IT & Managed Care
9 transactions totaling $4,069 million
Healthcare Facilities & Distributors
2 transactions totaling $175 million
Pharma & Biotech
14 transactions totaling $1,230 million
Supplies, Equipment & Services
4 transactions totaling $221 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
2 transactions totaling $344
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
October 12, 2021 - Bloomberg
GlaxoSmithKline Plc’s consumer unit is drawing interest from private equity firms in what could lead to the biggest buyout of all time, people with knowledge of the matter said. The drugmaker’s advisers are informally fielding interest in the operations alongside preparations for a listing, the people said, asking not to be identified because the information is private. Advent International, CVC Capital Partners and KKR & Co. are among potential suitors evaluating the business, they said. Blackstone Inc., Carlyle Group Inc. and Permira are also seen as likely suitors for the consumer arm, which could be valued at 40 billion pounds ($54 billion) or more in any deal, the people said.

October 14, 2021 - Fierce Biotech
You might think of the ABCs as a fun, simple-to-learn childhood game. But those three letters signify a group of proteins with mutations that destroy functions in multiple organs, and investors are pumping $100 million into Rectify Pharmaceuticals to modify genetic diseases. And the Cambridge, Massachusetts, biotech is founded by somebody who knows his ABCs: Chief Scientific Officer Jonathan Moore, Ph.D. As a founding scientist at Vertex Pharmaceuticals, Moore worked on treatments that targeted the ABC transporter family.

October 14, 2021 - Fierce Healthcare
Less than two months after the deal was announced, Headspace and Ginger have closed their merger, creating a $3 billion mental health company. The merger comes during a time of unprecedented global need for mental health services as the COVID-19 pandemic exacerbated existing behavioral health challenges. By combining Ginger's teletherapy services with Headspace's meditation and mindfulness app, the company now has a combined reach to 100 million consumers, according to the company.

October 14, 2021 - Fierce Biotech
A stacked lineup of industry vets from Eli Lilly, Versant, Amgen and more is teaming up to advance the field of multifunctional biotherapeutics. The seasoned executive team is launching Tentarix Biotherapeutics with the help of $50 million in series A fundraising. Co-led by Versant Ventures and Samsara BioCapital, the financing will help the team develop programs for oncology and autoimmune diseases via its technology platform, the company said Thursday. The biotech, which will be based in both Vancouver and San Diego, has assembled a team of 30 individuals to start off with. The team includes Paul Grayson at the helm as president and CEO.
Events Hosted or Attended by Bourne Partners

Dates TBD - Charlotte, NC

October 5, 2021 - Virtual Webinar

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA

Where there's a will there's a way! Discover what's possible with Tanner's Global Access Solutions.

Tanner is committed to supporting the causes of its teams and partners.

Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.